RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
Trial details
- Registry ID
- NCT07236606
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)NCT07236606 | RGNX | Phase 3 | Active not recruiting | 2028-04-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |